Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

11.19 +0.19 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,480,354
Open 10.98
Bid (Size) 10.45 (1)
Ask (Size) 11.33 (1)
Prev. Close 11.00
Today's Range 10.98 - 11.48
52wk Range 5.910 - 12.63
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Short Volatility Alert: Amicus Therapeutics, Inc.
On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga

Performance

YTD
-7.60%
-7.60%
1 Month
+42.01%
+42.01%
3 Month
+20.84%
+20.84%
6 Month
-6.59%
-6.59%
1 Year
+20.32%
+20.32%

More News

Read More
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Via Benzinga
Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
Via InvestorPlace
FDA Extends Review Of Amicus Therapeutics' AT-GAA For The Treatment Of Pompe Disease By Three Months
Via Benzinga
Recap: Amicus Therapeutics Q1 Earnings
Via Benzinga
Earnings Outlook For Amicus Therapeutics
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Via Benzinga
Amicus Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
Amicus Therapeutics Earnings Preview
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022
Via Benzinga
10 Biggest Price Target Changes For Friday
Via Benzinga
60 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher
Via Benzinga
Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge
Via Benzinga
45 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
Via Benzinga
The Week In SPAC News - Sunday, Oct. 3
Via Talk Markets
Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.